IndraLab

Statements



reach
"Marizomib treatment blocks the activation of NF-kappaB by SN-38 (the active metabolite of irinotecan) in CRC cells and results in the accumulation of the phosphorylated form of IkappaBalpha (a marker of inhibited NF-kappaB activity)."